In re Boeing (Aug. 14, 2026), the Delaware Court of Chancery, at the pleading stage of litigation, dismissed Caremark claims brought against directors and officers of The Boeing Company (the “Company”) after alleged manufacturing process defects led to a dramatic, mid-flight mechanical failure of a Boeing airplane, which followed two earlier catastrophic accidents due to alleged manufacturing defects in Boeing airplanes. The allegations included years-long, ongoing violations by the Company of manufacturing safety laws and regulations.
This significant ruling, penned by Justice Morgan T. Zurn (sitting by designation on the Court of Chancery), provides a detailed examination of the boundaries of director oversight duties under Delaware law, particularly in the context of complex manufacturing and safety-critical industries. The decision, which emanates from a Fried Frank memorandum authored by Maxwell Yim, Adam Cohen, Colum Weiden, Gail Weinstein, Philip Richter, and Steve Epstein, all Partners at Fried, Frank, Harris, Shriver & Jacobson LLP, offers crucial insights into the standard of proof required to sustain Caremark claims against corporate leadership. This analysis is part of the esteemed Harvard Law School Corporate Governance blog’s Delaware Law Series.
The case stems from a series of severe safety incidents involving Boeing aircraft. In two separate, tragic events in 2018 and 2019, Boeing 737 MAX aircraft crashed mid-flight, resulting in the loss of hundreds of lives. These disasters led to substantial financial penalties for the Company, including billions of dollars in fines and settlements, and prompted solemn commitments to regulators, the U.S. Department of Justice, and stockholders to overhaul its safety systems and corporate culture. The most recent incident, occurring in 2024, involved a Boeing 737 MAX-9 aircraft. During ascent to 15,000 feet, a mid-cabin door plug detached, creating a gaping hole in the fuselage. Fortunately, the aircraft executed a safe emergency landing, and only eight individuals sustained minor injuries.
Following this latest incident, plaintiffs filed suit, alleging that Boeing’s directors and officers had breached their oversight duties under the landmark Caremark standard. The core of their argument was that the leadership had, in bad faith, ignored numerous “red flags” signaling ongoing and systemic issues within the company’s airplane manufacturing safety protocols.
A Chronology of Safety Concerns and Legal Scrutiny
The events leading up to the Court of Chancery’s decision paint a grim picture of persistent safety challenges within Boeing’s manufacturing operations.
- October 29, 2018: A Lion Air Boeing 737 MAX 8 crashes into the Java Sea shortly after takeoff from Jakarta, Indonesia, killing all 189 people on board. Investigations later pointed to issues with the aircraft’s Maneuvering Characteristics Augmentation System (MCAS) and inadequate pilot training.
- March 10, 2019: An Ethiopian Airlines Boeing 737 MAX 8 crashes six minutes after takeoff from Addis Ababa, Ethiopia, killing all 157 passengers and crew. Similar to the Lion Air crash, concerns about the MCAS system and pilot training were raised.
- Post-2019: In the wake of these dual tragedies, Boeing faced intense scrutiny. The company grounded its global 737 MAX fleet for an extended period. Regulatory bodies, including the Federal Aviation Administration (FAA) and other international aviation authorities, launched comprehensive investigations and imposed strict conditions for the aircraft’s recertification. Boeing committed to significant reforms in its safety management systems and employee training programs.
- January 5, 2024: A Boeing 737 MAX-9 operated by Alaska Airlines experiences a catastrophic failure when a mid-cabin door plug blows out at approximately 16,000 feet. The aircraft makes an emergency landing, and no fatalities or serious injuries are reported, though the event triggers renewed concerns about manufacturing quality.
- February 2024: The National Transportation Safety Board (NTSB) initiates an investigation into the Alaska Airlines incident. Preliminary findings suggest the door plug was missing securing bolts.
- August 2026 (prior to the Court of Chancery ruling): A separate lawsuit is filed in federal court against Boeing directors and officers concerning alleged disclosure failures related to the door plug incident.
- August 4, 2026: The U.S. Court of Appeals for the Fourth Circuit issues a decision in the federal securities litigation, reversing a lower court’s class certification order. The appellate court found that plaintiffs had failed to present a non-speculative model for calculating class-wide damages, a significant setback for that litigation.
- August 14, 2026: The Delaware Court of Chancery, in In re Boeing, dismisses with prejudice the Caremark claims brought by stockholders against Boeing’s directors and officers.
The NTSB’s Findings and Regulatory Scrutiny
The NTSB’s investigation into the January 2024 door plug incident revealed a series of manufacturing lapses. The agency determined that the door plug detached because it was not secured by the four bolts that should have fastened it to the aircraft’s fuselage. These bolts had been removed by company personnel to access and replace defective rivets. Crucially, after the rivets were replaced, the bolts were not reinserted. Furthermore, the door plug was closed without a quality assurance inspection being conducted, and no records were created documenting the removal of the bolts. Adding to the concern, the employees involved in this specific task lacked prior experience in opening and closing door plugs.
The NTSB’s final report characterized the probable cause of the incident as “a series of production mishaps symptomatic of systemic nonconformance issues.”
Following the incident, the FAA conducted a post-accident audit that identified 97 alleged instances of regulatory noncompliance by Boeing, including significant failures to adhere to manufacturing quality control requirements. This audit resulted in demands for substantial fines from the FAA and other regulatory bodies.
The Court of Chancery’s Decision: A Deep Dive into Caremark Principles
The core of the In re Boeing decision lies in the court’s application of the Caremark standard, which defines a board of directors’ duty of oversight. This duty has two prongs: (i) directors must make a good faith effort to ensure that the corporation has adequate reporting and monitoring systems in place to address legal compliance and other critical risks; and (ii) directors must not act in bad faith by consciously disregarding clear warnings—or “red flags”—of potential illegal conduct or corporate wrongdoing that could lead to significant harm.
In this instance, the plaintiffs primarily invoked the second prong of the Caremark duty, arguing that the Boeing board had seen and deliberately ignored numerous “red flags” pertaining to systemic airplane manufacturing safety issues, ultimately leading to the door plug blowout.
The Board’s Diligence vs. Alleged Oversight Failures
Justice Zurn’s opinion meticulously details the board’s engagement with safety and compliance issues. The court stressed that the Board was paying “substantial attention” to safety, even if its efforts had not yet yielded the desired level of improvement. Evidence presented to the court indicated that the Board had established specific committees to oversee compliance risks related to airplane safety and quality: the Audit Committee and the Aerospace Safety Committee. These committees reportedly met regularly and provided frequent updates to the full Board.
The Aerospace Safety Committee was notably comprised of independent directors possessing extensive expertise in engineering, manufacturing, aviation, and safety. The Board itself convened regularly, with airplane safety being a consistent agenda item. Management provided updates on safety and quality risks, alongside operational performance and production targets. The Aerospace Safety Committee employed several specific reporting mechanisms to review key safety risks and incidents, while the Audit Committee annually received a Compliance Risk Management (CRM) Report detailing key compliance risks in manufacturing safety and proposed mitigation efforts. The court acknowledged that “These channels presented the Board with information about Boeing’s manufacturing challenges and efforts to address them.”
Defining Bad Faith: The Crucial Distinction
A pivotal aspect of the ruling is the court’s rigorous definition of "bad faith" under Caremark. The court emphasized that Caremark liability is not triggered by mere gross negligence or recklessness, which are typically associated with a breach of the duty of care. Instead, Caremark liability hinges on a specific form of bad faith: “intentional dereliction of duty” or “conscious disregard for one’s responsibilities.”
The court stated that fiduciaries who make a good faith effort to implement and attend to a reasonable board-level monitoring and reporting system have met their baseline duty. They are not liable for oversight failures if they genuinely believed they were reasonably performing their duties. Justice Zurn drew a stark contrast, noting that “There is a vast difference between an inadequate or flawed effort to carry out fiduciary duties and a conscious disregard for those duties.” The opinion further elaborated that an “even wider gulph between imperfect [legal] compliance and purposeful lawbreaking.”
In applying this standard, the court found that the plaintiffs’ allegations did not provide a reasonable inference that the Boeing Board had consciously disregarded its duties or intentionally violated laws or regulations.
Business Judgment and the Nature of Risk
The court also highlighted that the Board’s decisions regarding how to respond to the information it received on key risks were business-risk decisions entitled to the protection of the business judgment rule. Even though the Company had allegedly violated numerous regulatory requirements over several years, the court reiterated that the Board had established a reasonable information reporting system and was actively monitoring it. Consequently, the Board’s responses to the risks it identified, including instances of legal noncompliance, were viewed as part of the Board’s “quintessential function” in managing the Company’s operations and were not subject to judicial second-guessing.
A fundamental legal presumption exists that directors make decisions in good faith, “even if their actions turn out poorly in hindsight.” The court found no evidence suggesting that the Board had made a conscious decision to have the corporation violate laws or regulations.
When Reporting Becomes Evidence: The "Red Flag" Analysis
The court offered a nuanced perspective on the role of safety issues and regulatory noncompliance reported to the Board. It suggested that these reports might, in fact, serve as evidence that the Company’s information reporting system was functioning as intended. The plaintiffs had meticulously compiled 95 pages of allegations based on regular reports from the Audit Committee and Aerospace Safety Committee, contending that nearly every update on manufacturing risks constituted a “red flag.”
However, the court cautioned against such an interpretation. It noted that Caremark‘s purpose is precisely to “prod” directors toward greater care in monitoring corporate compliance with legal standards. Therefore, updates that address “general risks” could legitimately be seen as “evidence that the reporting system [was] working as it should.” The court warned that the plaintiffs’ approach risked “recasting the volume and depth of Boeing’s reporting from a best practice into evidence of disloyalty,” encapsulating this with the adage, “If everything is a red flag, then nothing is.”
To qualify as a “red flag” for Caremark purposes, a warning signal must meet several criteria:
- Necessity to Act: The signal must have sufficiently put the Board on notice of a “need to act”—meaning it must inspire a need so clear that ignoring it implies a conscious disregard of duty.
- Director Awareness: The warning must have actually been seen by the directors, being “bright enough to put the board on notice that the corporation was violating the law or otherwise headed for a corporate trauma.”
- Similarity of Misconduct: The warning must have implied misconduct sufficiently similar to that which ultimately caused the corporate trauma.
- Exclusion of Routine Risks: The signal must not have been related to routine business risks that fall within the Board’s purview of managing day-to-day operations.
The court concluded that several specific warning signals, as presented by the plaintiffs, did not meet this stringent definition of a “red flag” for Caremark purposes.
Federal Action vs. Delaware Claims: Divergent Standards
The court also addressed the plaintiffs’ reliance on the denial of a motion to dismiss in the parallel federal action. Justice Zurn clarified that the “scienter inquiries [in the two actions] were not the same.” The federal case focused on whether Boeing’s disclosure of its oversight (i.e., statements about its commitment to safety) was adequate, whereas the Delaware case concerned the sufficiency of the oversight itself.
While acknowledging that the federal court, in denying the motion to dismiss, “must have found” that the allegations met the Exchange Act’s scienter requirements, Justice Zurn found that the federal court’s decision lacked sufficient detail regarding the specific allegations and rationale relied upon. This lack of detailed reasoning prevented it from supporting a reasonable inference of bad faith in the Delaware context.
Broader Implications and a Potentially Narrower View of Liability
While the In re Boeing decision reiterates established Caremark principles, its analysis and tone suggest a potentially narrower view of director oversight liability compared to some more recent Delaware rulings. The article contrasts this decision with Brewer v. Turner (Regions Bank) (2025), where Chancellor Kathaleen St. J. McCormick adopted a broader interpretation.
In Regions Bank, the court considered a whistleblower complaint from a former executive a red flag, a departure from historical precedent that often viewed such complaints as mere accusations. Furthermore, the Regions Bank court held that a series of warnings, individually insufficient, could collectively constitute red flags. Crucially, it found that a year-and-a-half delay in addressing noncompliance, while the board deliberated on a plan, supported an inference of bad faith. The distinguishing factor in Regions Bank was the court’s perception that the board had made a deliberate decision to prioritize profits over legal compliance by delaying corrective actions.
The In re Boeing decision, by contrast, appears to draw a firmer line, emphasizing that boards are not liable for imperfect efforts or even flawed outcomes, as long as they can demonstrate a good-faith commitment to establishing and monitoring reasonable oversight systems. The ruling underscores that the mere existence of safety issues or regulatory noncompliance, when accompanied by a robust reporting and monitoring framework, does not automatically equate to bad faith or a conscious disregard of duty.
Practice Points for Corporate Directors and Officers
The In re Boeing ruling offers several key takeaways for corporate directors and officers navigating oversight responsibilities:
- Robust Reporting Systems are Paramount: Demonstrating the existence and active functioning of comprehensive reporting and monitoring systems for legal compliance and key risks is critical. This includes clear committee structures, regular meetings, and detailed reporting mechanisms.
- Documenting Diligence: Meticulous documentation of the Board’s engagement with safety and compliance issues is essential. This includes meeting minutes, committee reports, and records of management presentations.
- Distinguishing Bad Faith from Poor Outcomes: Directors must understand that Caremark liability requires proof of intentional dereliction of duty or conscious disregard, not merely a negative outcome or an inadequate effort.
- The Business Judgment Rule as a Shield: Decisions made in good faith regarding how to respond to identified risks are generally protected by the business judgment rule, even if those decisions prove to be imperfect in hindsight.
- Defining "Red Flags" Carefully: A clear understanding of what constitutes a “red flag” under Caremark is vital. Not every warning signal or piece of negative information will rise to this level, particularly if it pertains to routine business risks or if the Board is actively engaged in addressing it.
- Conscious Disregard is Key: The ultimate test for bad faith under Caremark often hinges on whether the Board consciously disregarded a known, significant risk, rather than simply struggling to effectively manage complex challenges.
The In re Boeing decision serves as a significant legal precedent, reinforcing the importance of demonstrating proactive and good-faith efforts in corporate oversight, while also providing clarity on the high bar plaintiffs must clear to establish liability under Caremark in the face of challenging operational and safety issues.
